2024
Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis
Odanović N, Schwann A, Zhang Z, Kapadia S, Kunnirickal S, Parise H, Tirziu D, Ilic I, Lansky A, Pietras C, Shah S. Long-term outcomes of ischaemia with no obstructive coronary artery disease (INOCA): a systematic review and meta-analysis. Open Heart 2024, 11: e002852. PMID: 39353703, PMCID: PMC11448144, DOI: 10.1136/openhrt-2024-002852.Peer-Reviewed Original ResearchConceptsCoronary Vasomotor Disorders International Study GroupRate of MACEReduced coronary flow reserveCoronary flow reservePrognosis of patientsVasospastic anginaPatient yearsMyocardial infarctionPrimary outcomeIncidence of primary outcomeLong-term prognosis of patientsSystematic reviewMeta-analysisLong-term prognosisInternational Study GroupAdverse cardiovascular eventsLong-term outcomesImaging stress testsMeta-analysis of studiesRandom-effects modelWeb of ScienceINOCACardiovascular eventsFollow-upVasomotor disorders
2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events
2019
First-in-Human Study of Paclitaxel Drug-Coated Chocolate Coronary Percutaneous Transluminal Coronary Angioplasty Balloon Catheter in De Novo Coronary Artery Lesions
Garcia-Lithgow C, Tirziu D, Zhou S, Bouras G, Shah T, Grubman D, Javier JJ, Mustapha JA, Abizaid A, Lansky AJ. First-in-Human Study of Paclitaxel Drug-Coated Chocolate Coronary Percutaneous Transluminal Coronary Angioplasty Balloon Catheter in De Novo Coronary Artery Lesions. JACC Cardiovascular Interventions 2019, 12: 2568-2570. PMID: 31857033, DOI: 10.1016/j.jcin.2019.08.044.Peer-Reviewed Original Research
2007
Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling.
Muinck ED, Nagy N, Tirziu D, Murakami M, Gurusamy N, Goswami SK, Ghatpande S, Engelman RM, Simons M, Das DK. Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling. Antioxidants & Redox Signaling 2007, 9: 437-45. PMID: 17280485, DOI: 10.1089/ars.2006.1501.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsAntimicrobial Cationic PeptidesApoptosisBlotting, WesternCell LineGenetic TherapyHumansHypoxia-Inducible Factor 1, alpha SubunitIn Situ Nick-End LabelingMaleMalondialdehydeMiceMice, Inbred C57BLMutationMyocardial Reperfusion InjuryReactive Oxygen SpeciesReceptor, Fibroblast Growth Factor, Type 1Signal TransductionTime FactorsConceptsCoronary flowMyocardial ischemic reperfusion injuryMyocardial ischemia-reperfusion injuryEmpty vectorIschemia-reperfusion injuryIschemic reperfusion injuryLVdP/dtVentricular developed pressureMin of ischemiaBaseline coronary flowMyocardial infarct sizeGene therapyReperfusion injuryCardioprotective abilityInfarct sizeDeveloped pressureHIF-1alpha proteinTTC stainingAortic flowHeart rateCardiomyocyte apoptosisEx vivoCardioprotectionHIF1alpha stabilizationHemodynamics